BioStock: Annexin´s CMO on patent strategy

Report this content

Stockholm-based Annexin Pharmaceuticals has recently obtained FDA approval for the company’s phase II study in RVO, a production patent in the US, and a patent agreement with Stanford University regarding the cancer area. The latter means stronger product protection in the US and the opportunity to broaden their project portfolio and develop ANXV as a treatment for cancer. BioStock contacted the company’s CMO and co-founder, Anna Frostegård, to find out more.

Read the full article about Annexin Pharmaceuticals at

This is a press release from BioStock - Connecting Innovation & Capital


Quick facts

BioStock: Annexin´s CMO on patent strategy
Tweet this